What role does albumin play in paclitaxel's binding mechanism?

Why does albumin bind paclitaxel so tightly?

Albumin binds paclitaxel through hydrophobic pockets in its structure. These pockets allow the drug to interact with multiple sites on the albumin molecule, creating a high-affinity binding. The natural fatty-acid binding sites on albumin take up lipophilic parts of the paclitaxel molecule, helping it remain soluble in blood plasma.

What happens when albumin releases paclitaxel at tumor sites?

Albumin-bound paclitaxel exploits the enhanced permeability and retention effect in tumors. Tumor cells often overexpress gp60 receptors and secrete albumin-binding protein SPARC. Both mechanisms promote albumin uptake into cancer cells, so when the complex reaches a tumor, the drug gradually dissociates from albumin and enters the cell.

How does albumin-bound paclitaxel differ from solvent-based paclitaxel?

Solvent-based paclitaxel uses Cremophor EL as a vehicle to solubilize the drug. This synthetic solvent causes hypersensitivity reactions and requires long infusion times. Albumin-bound paclitaxel avoids these issues by using human serum albumin as the carrier. The absence of toxic solvents means patients receive shorter infusions and less premedication.

When does albumin-based delivery lose advantage over traditional methods?

The technology loses some advantage if tumors do not express high levels of gp60 or SPARC. In such cases, passive diffusion may dominate, so the benefits of receptor-mediated uptake are not always guaranteed. Data show that some patient subgroups still show comparable or better outcomes with solvent-based formulations.

How much does albumin-bound paclitaxel cost compared to generic paclitaxel?

Albumin-bound paclitaxel trades off higher price for absence of solvent-related complications. The branded nab-paclitaxel product commands a premium price. [1]